Stockscreener 앱 받기
107.19
4.90%
5.01
시장 영업 전:
108.73
1.54
+1.44%
전일 마감가:
$102.18
열려 있는:
$104.81
하루 거래량:
1.60M
Relative Volume:
1.54
시가총액:
$26.90B
수익:
$3.53B
순이익/손실:
$-632.88M
주가수익비율:
-40.74
EPS:
-2.631
순현금흐름:
$-588.37M
1주 성능:
+9.28%
1개월 성능:
+13.06%
6개월 성능:
-5.05%
1년 성능:
-5.76%
1일 변동 폭
$104.40
$108.12
1주일 범위
$97.80
$108.12
52주 변동 폭
$81.20
$126.77
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
107.19 | 25.64B | 3.53B | -632.88M | -588.37M | -2.631 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It - Chartmill
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan - Yahoo Finance
BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial - TipRanks
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - Finviz
BNTX Stock Price, Forecast & Analysis | BIONTECH SE-ADR (NASDAQ:BNTX) - Chartmill
Scientists Question Pfizer, BioNTech's Vaccine Effectiveness - AASTOCKS.com
BioNTech, Pfizer See Covid Vaccine Capacity Rise to 3B Doses Next Yr - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition By Investing.com - Investing.com South Africa
FOSUN PHARMA Pairs with BioNTech to Supply BioNTech Vaccine to Germans in CN - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition - Investing.com
Pfizer Vaccine Effectiveness Sinks to 47% Half Yr Post-inoculation: Research - AASTOCKS.com
BioNTech: Their Vaccine Can Reduce Chance of Catching Severe Covid from Omicron Variant - AASTOCKS.com
Eli Lilly Upgraded, NVIDIA Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - MSN
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/29/2025 - Nasdaq
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd. - MarketBeat
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Finviz
New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech - TipRanks
BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206 - TipRanks
Research Analysts’ Weekly Ratings Updates for BioNTech (BNTX) - Defense World
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
New Pumitamig kidney cancer trial adds long-term optionality for Bristol-Myers Squibb and BioNTech - MSN
BioNTech's Strategic Pivot Gains Validation from Key Safety Research () - aktiencheck.de
Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright - Defense World
Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bellevue Group AG Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
HC Wainwright Has Positive Estimate for BioNTech Q4 Earnings - Defense World
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - MSN
Research Analysts Set Expectations for BioNTech Q4 Earnings - MarketBeat
Berenberg Bank Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street - Finviz
Invesco Ltd. Buys 35,958 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Amundi Lowers Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Altrinsic Global Advisors LLC Sells 123,995 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
ETFs investiert in BioNTech SE Sponsored ADR-AktienTradingView - TradingView - Alle Märkte im Blick
Dymon Asia Capital Singapore PTE. LTD. Makes New $1.86 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech's Oncology Pipeline Gains Momentum with Key Clinical Data () - aktiencheck.de
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.37%
0.24%
자본화:
|
볼륨(24시간):